The Food and Drug Administration's review for an emergency use authorization of Moderna’s COVID-19 vaccine for adolescents as young as 12 years old is being delayed as the agency takes a d
Moderna said the FDA needs more time to complete its review of its Covid-19 vaccine for 12-to-17-year-olds before granting emergency use authorization.
Moderna Inc. said on Sunday it has been told that the U.S. Food and Drug Administration will require additional time to complete its assessment of the company’s COVID-19 vaccine for
U.S. regulators are delaying their decision on Moderna's COVID-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation, the company said Sunday.
U.S. regulators are delaying their decision on Moderna’s COVID-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation, the company said Sunday.
The Food and Drug Administration is delaying a decision on whether to make Moderna's coronavirus vaccine available to adolescents because the agency needs more time to evaluate if the shot increases the risk of a rare cardiac side effect, the company said Sunday.
Shares in Moderna Inc. dropped at least 5% as trading opened Monday after a delay in the decision to approve the COVID-19 vaccine for adolescents ages 12-17.
US biotech firm Moderna said Sunday that American officials have delayed approving its Covid-19 vaccine for teenagers to allow more time to better assess the potential risk of developing myocarditis,…
The delay in the Food and Drug Administration’s (FDA) review of the Moderna COVID-19 vaccine for adolescents won’t impact the Biden administration’s vaccine rollout for children, White House officials said on Monday
